Work Here?
Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, which are proteins that help cells stick together and communicate. This targeted approach allows Pliant to create effective treatments for various fibrotic conditions. Unlike many competitors, Pliant focuses specifically on the science of fibrosis and integrin biology, aiming to reverse the effects of these diseases rather than just manage symptoms. The company's goal is to halt the progression of fibrotic diseases and restore normal organ function, ultimately improving the quality of life for patients.
Company Stage
IPO
Employees
51-200
Industries
Hardware, Biotechnology
Total Funding
$694.9M
Headquarters
N/A
Founded
2015
Find jobs on Simplify and start your career today